Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

Bristol Myers Squibb presented 56-week Phase 3 data for Camzyos in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. The article headline provides no efficacy or safety results, so the data’s clinical or commercial implications cannot be assessed.